Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-Controlled Double-Blind Phase 2 Study of TMG-123 in Type 2 Diabetes Mellitus
jRCT2080223642Phase 2
- Sponsor
- Teijin Pharma
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TMG-123 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Teijin Pharma.
02
Drugs
TMG-123
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223642.